via allAfrica.com, by Marian Shinn of the Democratic Alliance
For the past year two applications for field trials have been awaiting approval by the MCC. One is from the Centre for the Aids Programme of Research in South Africa (CAPRISA) for the second field trial of its world-acclaimed antiretroviral vaginal gel.
The second is from the University of the Western Cape-based International Centre for Innovation Partnerships for a field trial of a drug that could delay the onset of AIDS in HIV positive people. This drug is a breakthrough in the use of active extracts from the Sutherlandia indigenous plant.
Both these drug developments are funded, in part, by the Department of Science and Technology (DST).
A year ago CAPRISA's Tenofovir gel received world-wide scientific recognition based on the results of the successful pioneering field trial held in KwaZulu-Natal. In November 2010 the developers of this microbicide gel applied to the MCC for permission to launch a second field trial that would include women attending family planning clinics in KwaZulu-Natal.
Many of these women took part in the first trial and, since that first ended in March 2010, have been prevented from continuing to use the preventative gel because CAPRISA cannot obtain permission to start its new trial, for which about R28 million in funding from UNAids and the DST has been secured.
Read the rest.
[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]
For the past year two applications for field trials have been awaiting approval by the MCC. One is from the Centre for the Aids Programme of Research in South Africa (CAPRISA) for the second field trial of its world-acclaimed antiretroviral vaginal gel.Both these drug developments are funded, in part, by the Department of Science and Technology (DST).
A year ago CAPRISA's Tenofovir gel received world-wide scientific recognition based on the results of the successful pioneering field trial held in KwaZulu-Natal. In November 2010 the developers of this microbicide gel applied to the MCC for permission to launch a second field trial that would include women attending family planning clinics in KwaZulu-Natal.
Many of these women took part in the first trial and, since that first ended in March 2010, have been prevented from continuing to use the preventative gel because CAPRISA cannot obtain permission to start its new trial, for which about R28 million in funding from UNAids and the DST has been secured.
Read the rest.
[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]
No comments:
Post a Comment